Stock XOMAO XOMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials XOMA Corporation Nasdaq

Equities

XOMAO

US98419J4040

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-06-06 EDT 		5-day change 1st Jan Change
25.1 USD +0.44% Intraday chart for XOMA Corporation +0.08% -0.08%
05-09 Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M MT
05-09 XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 266.4 486.4 235.8 210.7 212.5 279.1 - -
Enterprise Value (EV) 1 266.4 486.4 235.8 210.7 212.5 279.1 279.1 279.1
P/E ratio -119 x 56.6 x 32.1 x -9.29 x -4.58 x -12.7 x -18.2 x -55.3 x
Yield - - - - - - - -
Capitalization / Revenue 14.5 x 16.6 x 6.18 x 35 x 44.7 x 13.3 x 10.4 x 7.3 x
EV / Revenue 14.5 x 16.6 x 6.18 x 35 x 44.7 x 13.3 x 10.4 x 7.3 x
EV / EBITDA -69 x 39.1 x 13.4 x -12.1 x -5.19 x -28.5 x -46.5 x 64.9 x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 9,758 11,022 11,311 11,451 11,488 11,639 - -
Reference price 2 27.30 44.13 20.85 18.40 18.50 23.98 23.98 23.98
Announcement Date 20-03-10 21-03-10 22-03-08 23-03-09 24-03-08 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 18.37 29.38 38.16 6.027 4.758 21 26.93 38.23
EBITDA 1 -3.86 12.44 17.54 -17.41 -40.95 -9.8 -6 4.3
EBIT 1 -3.885 12.42 17.53 -17.41 -41.85 -8.4 -3.3 5.2
Operating Margin -21.15% 42.25% 45.94% -288.93% -879.53% -40% -12.25% 13.6%
Earnings before Tax (EBT) 1 -1.982 11.8 15.89 -17.12 -40.83 -17.3 -14.35 -4.95
Net income 1 -1.982 8.793 7.787 -22.58 -46.3 -22.07 -15.7 -5.1
Net margin -10.79% 29.92% 20.41% -374.58% -973.16% -105.08% -58.29% -13.34%
EPS 2 -0.2300 0.7800 0.6500 -1.980 -4.040 -1.893 -1.317 -0.4333
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 20-03-10 21-03-10 22-03-08 23-03-09 24-03-08 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 35.94 3.107 0.983 0.451 1.486 0.437 1.658 0.83 1.833 1.49 9.147 4.673 5.64
EBITDA 1 30.37 -2.063 -4.766 -4.368 -6.21 -9.944 -5.732 -5.563 -19.71 -7.002 3 -4.4 -1.5
EBIT 1 30.36 -2.065 -4.767 -4.372 -6.21 -10.17 -5.957 -5.787 -19.93 -7.004 2.25 -2.95 -0.7
Operating Margin 84.48% -66.46% -484.94% -969.4% -417.9% -2,327.23% -359.29% -697.23% -1,087.51% -470.07% 24.6% -63.12% -12.41%
Earnings before Tax (EBT) 1 29.94 -2.28 -4.67 -4.178 -5.991 -9.813 -5.4 -5.509 -20.11 -8.595 - -5.4 -3.25
Net income 1 19.74 -3.648 -6.038 -5.546 -7.344 -11.18 -6.768 -6.877 -21.48 -9.963 -3.1 -7.167 -5.5
Net margin 54.93% -117.41% -614.24% -1,229.71% -494.21% -2,558.58% -408.2% -828.55% -1,171.69% -668.66% -33.89% -153.35% -97.52%
EPS 2 1.670 -0.3200 -0.5300 -0.4800 -0.6400 -0.9800 -0.5900 -0.6000 -1.870 -0.8600 -0.2633 -0.6133 -0.4667
Dividend per Share - - - - - - - - - - - - -
Announcement Date 22-03-08 22-05-05 22-08-04 22-11-03 23-03-09 23-05-09 23-08-08 23-11-07 24-03-08 24-05-09 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - - - - - - - -
Capex / Sales - - - - - - - -
Announcement Date 20-03-10 21-03-10 22-03-08 23-03-09 24-03-08 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for XOMA Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
23.98 USD
Average target price
58 USD
Spread / Average Target
+141.87%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.72% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.19% 108B
BIONTECH SE Stock BioNTech SE
-4.93% 24.57B
ARGENX SE Stock argenx SE
+3.23% 22.82B
GENMAB A/S Stock Genmab A/S
-10.44% 18.19B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.54B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.31% 16.5B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.44% 13.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.89% 11.1B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XOMA Stock
  4. XOMAO Stock
  5. Financials XOMA Corporation